Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-04-04 20:37 | 2025-03-03 | CPIX | CUMBERLAND PHARMACEUTICALS INC | Jones James | Director | BUY | $5.24 | 168 | $881 | 42,814 |
| 2025-04-04 20:36 | 2025-03-03 | CPIX | CUMBERLAND PHARMACEUTICALS INC | Krogulski Kenneth | Director | BUY | $5.20 | 875 | $4,548 | 283,718 |
| 2025-04-04 20:37 | 2025-03-03 | CPIX | CUMBERLAND PHARMACEUTICALS INC | KAZIMI A J | Director, Officer, 10% owner | BUY | $5.24 | 168 | $881 | 5,698,906 |
| 2025-04-05 00:20 | 2025-04-02 | PTCT | PTC THERAPEUTICS, INC. | Golden Lee Scott | Officer | SELL | $46.95 | 897 | $42,114 | 75,997 |
| 2025-04-04 23:10 | 2025-04-03 | CYTK | CYTOKINETICS INC | Harrington Robert Arthur | Director | SELL | $39.43 | 450 | $17,744 | 14,658 |
| 2025-04-05 02:33 | 2025-04-03 | EWTX | Edgewise Therapeutics, Inc. | ORBIMED ADVISORS LLC | Director, 10% owner | BUY | $20.13 | 496,771 | $10,000,000 | 443,792 |
| 2025-04-05 02:27 | 2025-04-02 | MNPR | Monopar Therapeutics | Tactic Pharma LLC | 10% owner | SELL | $35.00 | 33,334 | $1,166,690 | 822,255 |
| 2025-04-03 23:21 | 2025-04-02 | VTYX | Ventyx Biosciences, Inc. | Nuss John | Officer | SELL | $1.07 | 1,887 | $2,019 | 467,226 |
| 2025-04-04 03:44 | 2025-04-01 | BFRG | BullFrog AI Holdings, Inc. | Singh Vininder | Director, Officer, 10% owner | SELL | $1.51 | 44,105 | $66,409 | 2,348,341 |
| 2025-04-03 23:05 | 2025-04-01 | NUVB | Nuvation Bio Inc. | Mashal Robert | Director | BUY | $1.67 | 100,000 | $166,990 | 200,000 |
| 2025-04-03 23:21 | 2025-04-01 | ARQT | Arcutis Biotherapeutics Inc. | Welgus Howard G. | Director | SELL | $15.12 | 10,000 | $151,236 | 121,944 |
| 2025-04-04 00:11 | 2025-04-01 | BBIO | BridgeBio Pharma, Inc. | Ellis Andrea | Director | OPT+S | $34.05 | 30,000 | $1,021,500 | 12,000 |
| 2025-04-03 23:21 | 2025-04-02 | ARQT | Arcutis Biotherapeutics Inc. | Topper David Joseph | Officer | SELL | $15.80 | 9,600 | $151,698 | 182,774 |
| 2025-04-04 00:07 | 2025-04-02 | ZLAB | Zai Lab Ltd | Edmondson Frazor Titus III | Officer | OPT+S | $35.89 | 4,369 | $156,821 | 27,217 |
| 2025-04-04 00:07 | 2025-04-02 | ZLAB | Zai Lab Ltd | Du Ying | Director, Officer | OPT+S | $35.89 | 5,808 | $208,472 | 476,046 |
| 2025-04-04 00:06 | 2025-04-02 | ZLAB | Zai Lab Ltd | Chen Yajing | Officer | OPT+S | $35.89 | 5,280 | $189,520 | 25,471 |
| 2025-04-04 00:06 | 2025-04-02 | ZLAB | Zai Lab Ltd | Smiley Joshua L | Officer | OPT+S | $35.89 | 11,740 | $421,396 | 63,554 |
| 2025-04-03 23:15 | 2025-04-01 | HRMY | Harmony Biosciences Holdings, Inc. | Kapadia Sandip | Officer | SELL | $32.54 | 6,987 | $227,386 | 0 |
| 2025-04-04 00:36 | 2025-04-01 | MLYS | Mineralys Therapeutics, Inc. | Rodman David Malcom | Officer | OPT+S | $15.76 | 55,771 | $879,007 | 116,704 |
| 2025-04-04 00:06 | 2025-04-02 | ZLAB | Zai Lab Ltd | Amado Rafael | Officer | OPT+S | $35.89 | 7,541 | $270,677 | 42,816 |
| 2025-04-04 00:04 | 2025-04-01 | BGNE | BeOne Medicines Ltd. | Wu Xiaobin | Officer | OPT+S | $281.40 | 51,921 | $14,610,372 | 0 |
| 2025-04-03 23:56 | 2025-04-01 | RNA | Avidity Biosciences, Inc. | Gallagher Kathleen P. | Officer | OPT+S | $27.83 | 5,875 | $163,486 | 50,554 |
| 2025-04-03 23:30 | 2025-04-02 | SYBX | SYNLOGIC, INC. | Dooley Mary Beth | Officer | SELL | $1.20 | 144 | $173 | 12,901 |
| 2025-04-04 01:05 | 2025-04-01 | ALMS | Alumis Inc. | Babler Martin | Director, Officer | BUY | $6.44 | 15,650 | $100,733 | 106,454 |
| 2025-04-03 23:28 | 2025-04-02 | TLPH | TALPHERA, INC. | Angotti Vincent J. | Director, Officer | BUY | $0.59 | 213,310 | $125,000 | 403,769 |
| 2025-04-04 01:05 | 2025-04-01 | ALMS | Alumis Inc. | Colowick Alan | Director | BUY | $7.04 | 18,404 | $129,544 | 18,404 |
| 2025-04-04 00:32 | 2025-04-01 | JAZZ | Jazz Pharmaceuticals plc | COZADD BRUCE C | Director, Officer | SELL | $123.75 | 1,500 | $185,625 | 440,307 |
| 2025-04-03 23:25 | 2025-04-01 | INSM | INSMED Inc | Lewis William | Director, Officer | OPT+S | $73.58 | 6,830 | $502,577 | 233,924 |
| 2025-04-02 23:30 | 2025-03-31 | XOMA | XOMA Royalty Corp | Sitko Bradley | Officer | BUY | $21.04 | 1,245 | $26,201 | 3,045 |
| 2025-04-03 01:48 | 2025-04-01 | TERN | Terns Pharmaceuticals, Inc. | Kuriakose Emil | Officer | SELL | $2.49 | 952 | $2,366 | 53,317 |
| 2025-04-02 23:12 | 2025-04-01 | AMRX | Amneal Pharmaceuticals Inc. | Patel Gautam | Director | SELL | $8.30 | 80,000 | $664,000 | 1,728,886 |
| 2025-04-03 00:12 | 2025-03-31 | AMLX | Amylyx Pharmaceuticals, Inc. Common Stock | Mazzariello Gina | Officer | SELL | $3.48 | 9,192 | $31,954 | 187,969 |
| 2025-04-02 23:57 | 2025-03-31 | AMLX | Amylyx Pharmaceuticals, Inc. Common Stock | Cohen Joshua B | Director, Officer | SELL | $3.47 | 21,490 | $74,482 | 3,355,280 |
| 2025-04-02 23:52 | 2025-03-31 | AMLX | Amylyx Pharmaceuticals, Inc. Common Stock | Klee Justin B. | Director, Officer | SELL | $3.46 | 21,490 | $74,454 | 3,355,276 |
| 2025-04-02 23:30 | 2025-04-01 | XOMA | XOMA Royalty Corp | BURNS THOMAS M. | Officer | BUY | $25.46 | 1,000 | $25,460 | 2,000 |
| 2025-04-03 01:29 | 2025-03-31 | VKTX | Viking Therapeutics, Inc. | Rouan Sarah Kathryn | Director | BUY | $24.15 | 1,240 | $29,943 | 1,240 |
| 2025-04-02 23:37 | 2025-03-31 | BNTC | Benitec Biopharma Inc. | SUVRETTA CAPITAL MANAGEMENT, LLC | Director, 10% owner | BUY | $12.83 | 16,497 | $211,736 | 1,068,701 |
| 2025-04-03 00:00 | 2025-03-31 | ABBV | AbbVie Inc. | Stewart Jeffrey Ryan | Officer | OPT+S | $210.08 | 58,832 | $12,359,503 | 53,234 |
| 2025-04-03 00:38 | 2025-04-01 | SLNO | SOLENO THERAPEUTICS INC | Hirano Patricia C | Officer | SELL | $70.11 | 3,782 | $265,156 | 27,036 |
| 2025-04-03 02:02 | 2025-03-31 | ZYME | Zymeworks Inc. | EcoR1 Capital, LLC | Director, 10% owner | BUY | $11.75 | 127,415 | $1,497,317 | 17,382,566 |
| 2025-04-03 00:14 | 2025-03-31 | AMLX | Amylyx Pharmaceuticals, Inc. Common Stock | Bedrosian Camille L | Officer | SELL | $3.47 | 12,425 | $43,082 | 194,375 |
| 2025-04-03 01:45 | 2025-04-01 | AMPH | Amphastar Pharmaceuticals Inc. | Petersen Floyd F. | Director | SELL | $28.38 | 500 | $14,190 | 73,909 |
| 2025-04-03 04:01 | 2025-03-31 | IBO | IMPACT BIOMEDICAL INC. | Chan Heng Fai Ambrose | Director, 10% owner | SELL | $1.15 | 2,526,918 | $2,912,778 | 734,058 |
| 2025-04-03 00:22 | 2025-03-31 | AMLX | Amylyx Pharmaceuticals, Inc. Common Stock | FRATES JAMES M | Officer | SELL | $3.47 | 10,896 | $37,806 | 290,988 |
| 2025-04-02 22:46 | 2025-03-31 | LYEL | Lyell Immunopharma, Inc. | BRAWLEY OTIS W | Director | BUY | $0.56 | 35,640 | $19,958 | 35,640 |
| 2025-04-03 03:20 | 2025-03-31 | CORT | CORCEPT THERAPEUTICS INC | Maduck Sean | Officer | OPT+S | $100.62 | 100,590 | $10,121,597 | 85,622 |
| 2025-04-03 03:15 | 2025-03-31 | CORT | CORCEPT THERAPEUTICS INC | Lyon Joseph Douglas | Officer | OPT+S | $100.51 | 200,650 | $20,167,954 | 9,009 |
| 2025-04-03 03:08 | 2025-04-01 | CORT | CORCEPT THERAPEUTICS INC | Guyer William | Officer | OPT+S | $114.51 | 678 | $77,639 | 5,487 |
| 2025-04-03 03:01 | 2025-03-31 | CORT | CORCEPT THERAPEUTICS INC | BELANOFF JOSEPH K | Director, Officer | SELL | $94.92 | 35,452 | $3,365,012 | 2,981,985 |
| 2025-04-03 01:06 | 2025-04-01 | RMTI | ROCKWELL MEDICAL, INC. | Strobeck Mark | Director, Officer | SELL | $1.08 | 6,926 | $7,480 | 124,678 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.